CG Oncology, Inc. Common stock (CGON : NASDAQ)
Common Stock
$63.47
USD
-0.49 (-0.77%)
Last updated: 2026-10-29
Follow CGON
CGON
CG Oncology, Inc. Common stock
WealthAwesomePerformance
1 Day
-0.77%
1 Week
+1.49%
1 Month
-10.00%
YTD
+5.03%
Key Statistics
Market Cap
$5.63B
52W High
$80.97
52W Low
$35.80
P/E Ratio
-
50 Day MA
$69.69
200 Day MA
$65.86
Beta
0.28
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/29/2026 | $64.53 | $65.74 | $63.08 | $63.47 | $63.47 | 782,618 |
| 10/28/2026 | $62.53 | $64.11 | $62.30 | $63.96 | $63.96 | 942,250 |
| 10/27/2026 | $61.46 | $64.13 | $59.96 | $62.94 | $62.94 | 709,340 |
| 10/26/2026 | $61.76 | $62.80 | $61.06 | $61.56 | $61.56 | 880,160 |
| 10/23/2026 | $62.36 | $62.36 | $59.86 | $61.71 | $61.71 | 1,065,000 |
| 10/22/2026 | $61.95 | $63.19 | $61.40 | $62.54 | $62.54 | 579,518 |
| 10/21/2026 | $62.43 | $63.57 | $61.27 | $62.24 | $62.24 | 530,035 |
| 10/20/2026 | $60.16 | $62.71 | $60.16 | $61.93 | $61.93 | 761,801 |
| 10/19/2026 | $60.44 | $61.25 | $59.22 | $59.96 | $59.96 | 1,215,167 |
| 10/16/2026 | $61.86 | $62.00 | $59.37 | $59.85 | $59.85 | 1,079,700 |
Analyst Price Targets
Based on 15 analysts covering CGON · as of Oct 5, 2026
Wall Street analysts forecast CGON stock price to rise 43.5% over the next 12 months.
Consensus
Strong Buy4.60 / 5.00
Avg. Target
US$91.08
+43.5% Upside
Current Price
US$63.47
Last close
Analyst Breakdown (15 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CGON's historical volatility
30-Day Vol
44.7%
Annualized
90-Day Vol
44.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$53.09
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$59.80 | US$51.25 – US$69.79 |
| 60 trading days | US$56.35 | US$45.29 – US$70.10 |
| 90 trading days | US$53.09 | US$40.63 – US$69.37 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About CG Oncology, Inc. Common stock
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.
Financials
- Revenue (TTM)
- $6.23M
- EBITDA
- $-249.66M
- Profit Margin
- 0.00%
- ROE (TTM)
- -26.41%
- EPS (Diluted)
- -2.69
- Book Value
- 11.65
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About CGON.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| PCLA | PicoCELA Inc. American Depositary Shares | $11.10 | +86.09% |
| GENVR | Gen Digital Inc. Contingent Value Rights | $1.75 | +65.09% |
| NCPL | Netcapital Inc | $1.78 | +61.82% |
| INLF | INLIF LIMITED Ordinary Shares | $0.27 | +47.22% |
| XCH | XCHG Limited American Depositary Share | $3.46 | +41.80% |
| AMPGZ | Amplitech Group, Inc. Series B Right | $0.05 | +40.80% |
| SGLY | Singularity Future Technology Ltd | $0.50 | +40.17% |
| JFIN | Jiayin Group Inc | $1.72 | +37.60% |
CGON.US news timeline
1 article covering CGON.US, most recent first
Latest